Protocols
5 protocol(s) meet the specified criteria
PI: Weiss, Jared
Protocol No.TitleStatus
A8081001Phase 1 Safety, Pharmacokinetic and Pharmacodynamic Study of PF-02341066, A C-Met/HGRF Selective Tyrosine Kinase Inhibitor, Administered Orally to Patients with Advanced Cancer Open
CALGB30607Randomized, Phase III, Double-Blind Placebo-Controlled Trial of Sunitinib (NSC #736511, IND #74019) as Maintenance Therapy in Non-Progressing Patients Following an Initial Four Cycles of Platinum-Based Combination Chemotherapy in Advanced, Stage IIIB/IV Non-Small Cell Lung Cancer Open (affiliates only)
LCCC1509Pembrolizumab and Radiation for Locally Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN) not Eligible for Cisplatin TherapyOpen
LCCC1516A Randomized, Non-comparative Three Arm Phase II Trial of Sequential Consolidation with Pembrolizumab followed by Nab-paclitaxel, Sequential Consolidation with Nab-paclitaxel followed by Pembrolizumab and Concurrent Consolidation with Nab-paclitaxel and Pembrolizumab after Standard First-Line Induction Chemotherapy in Advanced NSCLCOpen
M14-360A Phase I Dose Escalation and Phase 2 Randomized, Placebo-Controlled Study of the Efficacy and tolerability of Veliparib in Combination with Paclitaxel/Carboplatin-Based Chemoradiotherapy Followed by Veliparib and Paclitaxel/Carboplatin Consolidation in Subjects with Stage III Non-Small Cell Lung Cancer (NSCLC)Open